Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Von Willebrand Disease
Interventions
OTHER

Patients using Wilate as standard of care

Patients with von Willebrand Disease using Wilate for a period of 2 years.

Trial Locations (24)

10003

Hospital San Pedro de Alcantara, Cáceres

23219

Virginia Commonwealth University, Richmond

28040

Hospital Fundacion Jiminez Diaz, Madrid

33155

Nicklaus Children's Hospital, Miami

84112

University of Utah, Salt Lake City

90502

Los Angeles Biomedical Research Institute, Torrance

Unknown

Fundación de la Hemofilia de Salta, Salta

University of Alberta, Edmonton

Vancouver General Hospital, Vancouver

St. John Regional Hospital, Saint John

Eastern Regional Health Authority, St. John's

McMaster University, Hamilton

Children's Hospital of Eastern Ontario, Ottawa

St. Michael's Hospital, Toronto

University Hospital Ostrava, Ostrava-Poruba

Werlhof-Institut, Hanover

Centro Hospitalar Cova da Beira, Covilha

Skåne University Hospital, Malmo

Great Ormond Street Hospital for Children, London

Hospital Pereira Rossell, Montevideo

Sanatorio Americano, Montevideo

K7L 3N6

Queens University, Kingston

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

09006

Hospital Universitario de Burgos, Burgos

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY